Skip to main content

Table 4 Top 5 most frequent regimens during first-, second-, and third-line therapy

From: Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas

First-line therapy n (%) Second-line therapy n (%) Third-line therapy n (%)
All patients (N = 1227) All patients (N = 476) All patients (N = 189)
Docetaxel–gemcitabine 325 (26.5) Doxorubicin 101 (21.2) Doxorubicin 28 (14.8)
Doxorubicin 231 (18.8) Docetaxel–gemcitabine 83 (17.4) Docetaxel–gemcitabine 21 (11.1)
Gemcitabine 112 (9.1) Gemcitabine 41 (8.6) Gemcitabine 21 (11.1)
Paclitaxel 68 (5.5) Paclitaxel 21 (4.4) Ifosfamide 15 (7.9)
Bevacizumab 41 (3.3) Ifosfamide 20 (4.2) Dacarbazine –
Leiomyosarcomas (N = 341)   Leiomyosarcomas (N = 148)   Leiomyosarcomas (N = 66)  
Docetaxel–gemcitabine 136 (39.9) Doxorubicin 41 (27.7) Doxorubicin 12 (18.2)
Doxorubicin 64 (18.8) Docetaxel–gemcitabine 35 (23.7) Docetaxel–gemcitabine –
Gemcitabine 43 (12.6) Gemcitabine – Gemcitabine –
Carboplatin-paclitaxel – Docetaxel – Carboplatin-paclitaxel –
Dacarbazine-doxorubicin – Dacarbazine – Ifosfamide –
Doxorubicin–ifosfamide –     
Temozolomide –     
Undifferentiated pleomorphic sarcoma (N = 158)   Undifferentiated pleomorphic sarcoma (N = 64)   Undifferentiated pleomorphic sarcoma (N = 24)  
Docetaxel–gemcitabine 36 (22.8) Docetaxel–gemcitabine 1 3 (20.3) Doxorubicin –
Doxorubicin 32 (20.3) Doxorubicin – Docetaxel–gemcitabine –
Gemcitabine 13 (8.2) Ifosfamide – Dacarbazine –
Ifosfamide 11 (7.0) Gemcitabine – Ifosfamide –
Doxorubicin–ifosfamide – Paclitaxel –   
   Temozolomide –   
Liposarcomas (N = 140)   Liposarcomas (N = 45)   Liposarcomas (N = 15)  
Doxorubicin 34 (24.3) Docetaxel–gemcitabine 11 (24.4) Ifosfamide –
Docetaxel–gemcitabine 31 (22.1) Doxorubicin – Gemcitabine –
Bevacizumab 13 (9.3) Gemcitabine –   
Gemcitabine 12 (8.6) Docetaxel-doxorubicin-gemcitabine –   
Doxorubicin–ifosfamide – Ifosfamide –   
Ifosfamide –     
Vascular sarcomas (N = 130)   Vascular sarcomas (N = 60)   Vascular sarcomas (N = 21)  
Paclitaxel 52 (40.0) Doxorubicin 18 (30.0) Doxorubicin –
Doxorubicin 22 (16.9) Paclitaxel – Doxorubicin–ifosfamide –
Docetaxel–gemcitabine – Docetaxel–gemcitabine – Docetaxel –
Doxorubicin–ifosfamide – Gemcitabine – Docetaxel–gemcitabine –
Docetaxel – Docetaxel – Paclitaxel –
Fibroblastic/Myofibroblastic sarcomas (N = 58)   Fibroblastic/Myofibroblastic sarcomas (N = 19)   Fibroblastic/Myofibroblastic sarcomas (N = –)  
Docetaxel–gemcitabine 16 (27.6) Bevacizumab – Docetaxel–gemcitabine –
Doxorubicin – Docetaxel–gemcitabine – Gemcitabine –
Bevacizumab – Bevacizumab-temozolomide –   
Gemcitabine – Gemcitabine –   
Cisplatin – Temozolomide –   
Doxorubicin–ifosfamide –     
Nerve sheath sarcomas (N = 24)   Nerve sheath sarcomas (N = –)   Nerve sheath sarcomas (N = –)  
Doxorubicin – Doxorubicin –   
Docetaxel–gemcitabine –     
Gemcitabine –     
Doxorubicin–ifosfamide –     
Ifosfamide –     
Rhabdomyosarcomas (N = 28)   Rhabdomyosarcomas (N = 15)   Rhabdomyosarcomas (N = –)  
Docetaxel–gemcitabine – Doxorubicin –   
Carboplatin-paclitaxel – Cyclophosphamide-doxorubicin-vincristine –   
Cyclophosphamide-dactinomycin-vincristine –     
Cyclophosphamide-doxorubicin –     
Cyclophosphamide-doxorubicin-vincristine –     
Doxorubicin –     
Synovial sarcomas (N = 21)   Synovial sarcomas (N = –)   Synovial sarcomas (N = –)  
Docetaxel–gemcitabine – Dacarbazine –   
Doxorubicin – Doxorubicin –   
Temozolomide – Ifosfamide –   
Others/NOS (N = 327)   Others/NOS (N = 109)   Others/NOS (N = 46)  
Docetaxel–gemcitabine 81 (24.8) Docetaxel–gemcitabine 14 (12.8) Gemcitabine –
Doxorubicin 61 (18.7) Doxorubicin 14 (12.8) Ifosfamide –
Gemcitabine 30 (9.2) Gemcitabine 12 (11.0) Dacarbazine –
Carboplatin-paclitaxel 16 (4.9) Carboplatin-paclitaxel – Docetaxel–gemcitabine –
Paclitaxel 12 (3.7) Docetaxel – Doxorubicin –
   Doxorubicin–ifosfamide –   
   Ifosfamide –   
  1. Only showing treatment regimens received by more than 1 patient
  2. NOS not otherwise specified
Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329